U
SciSparc Ltd. SPRC
$1.01 -$0.04-3.81% NASDAQ
Recommendation
Prev Close
$1.01
Volume
12,679
Avg Vol (90D)
4,514,169
Market Cap
$4.39M
Dividend & Yield
--
52-Week Range
$0.96 - $13.23
P/E (TTM)
0.19
EPS (TTM)
$5.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
SciSparc (NASDAQ:SPRC) and ARS Pharmaceuticals (NASDAQ:SPRY) Financial Contrast
1/19/2026 - Ticker Report
SciSparc to acquire a treasury of patents for the endoscope market
1/13/2026 - TipRanks Financial Blog
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- ...
1/13/2026 - GuruFocus
SciSparc to acquire a treasury of patents for the endoscope market
1/13/2026 - The Fly
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
1/13/2026 - Globe Newswire
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
1/12/2026 - GuruFocus
SciSparc receives Nasdaq notice over stockholders' equity shortfall
1/12/2026 - Seeking Alpha - Healthcare
SciSparc receives Nasdaq notice over stockholders' equity shortfall
1/12/2026 - Seeking Alpha - Israel Stocks
SciSparc receives noncompliance notification from Nasdaq
1/12/2026 - The Fly
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
1/12/2026 - Globe Newswire
SciSparc Calls February 2026 Meeting to Approve New Deloitte Auditor and Executive Equity Awards
12/31/2025 - TipRanks Financial Blog
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary ...
12/30/2025 - GuruFocus
SciSparc (SPRC) Secures Patent for Innovative Opioid Combination
12/30/2025 - GuruFocus
SciSparc says Neurothera Labs granted patent by Israeli Patent Office
12/30/2025 - The Fly
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
12/30/2025 - Globe Newswire
SciSparc's NeuroThera Labs Eyes Quantum Leap with New Acquisition
12/2/2025 - TipRanks Financial Blog
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum ...
12/2/2025 - GuruFocus
SciSparc (SPRC) Acquires Interest in Quantum Computing Bio Data Company
12/2/2025 - GuruFocus
NeuroThera to acquire 55% stake in quantum computing bio data company
12/2/2025 - TipRanks Financial Blog
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
12/2/2025 - Globe Newswire
SciSparc (SPRC) to Acquire Patents for Innovative Endoscopic Systems
12/1/2025 - GuruFocus
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an ...
12/1/2025 - GuruFocus
SciSparc plans to enter GERD device market with IP portfolio acquisition
12/1/2025 - The Fly
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
12/1/2025 - Globe Newswire
Why SciSparc Stock Is Gaining Today
11/26/2025 - Benzinga
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
--
Total Debt (Q)
$0.00
Total Liabilities (Q)
--
Book Value Per Share (Q)
--
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, November 20, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Apr 20 and 24 (est)
Price History
Loading...
Beta
1.89
7-Day Total Return
-17.55%
30-Day Total Return
-54.91%
60-Day Total Return
-73.35%
90-Day Total Return
-43.89%
Year to Date Total Return
-27.86%
1-Year Total Return
-91.82%
2-Year Total Return
-98.61%
3-Year Total Return
-99.81%
5-Year Total Return
--
52-week Low
Jan 22, 2026 - $0.96
52-week High
Jan 24, 2025 - $13.23
Valuation
Market Cap
$4.39M - Nano Cap
Enterprise Value
$5.66M
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
520.50K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
scisparc.com
Phone Number
972 7 334 47180
Address
Tower A
2nd Floor - 20 Raul Wallenberg Street
Tel Aviv, 6971916
Country
Israel
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed